Helix Research Network: Understanding Genetic Predisposition to Disease

This study, called the Helix Research Network, aims to create a large collection of genetic and health information to help researchers better understand diseases. They will do this by performing exome sequencing (looking at all the protein-coding genes in your DNA) on samples from participants. The goal is to find genetic factors that influence disease risk, how diseases progress, and how people respond to treatments. This information could lead to better ways to diagnose and treat illnesses. You can join if you are 18 or older and can follow the study's instructions. The study is ongoing and plans to enroll a very large number of participants.

Study design
This is an observational study, meaning researchers will collect information without giving you a specific treatment. It plans to enroll 2,000,000 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Researchers plan to re-contact participants and aggregate data throughout the study, which is expected to last an average of 10 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06057181

Helix Research Network

Recruiting
Not specifiedAges 18+Observational
Helix, Inc
~2,000,000 participants
Updated 2026-03-23 on ClinicalTrials.gov
What's tested:Exome sequencing

At a glance

Recruiting sites
14 of 14 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Establish a Research Network
Measured over Through study completion, average 10 years
+5 more outcomes measured
Genetic Predisposition to Disease
Genetics Disease
14 sites across 11 states
North Carolina2
Ohio2
Pennsylvania2
Indiana1
Minnesota1
Nebraska1
Nevada1
New York1
  • William Lee, PhD · PRINCIPAL_INVESTIGATOR · Helix, Inc

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

18 years and older
Willing and able to comply with all aspects of the protocol

Exclusion

History of allogenic bone marrow transplant
History of allogenic stem cell transplant
Anything that would place the individual at increased risk or preclude an individual's: 1) full compliance with study requirements; or 2) completion of the study based on the assessment from local consenting and enrolling Investigators.
  • Establish a Research NetworkThrough study completion, average 10 years

    Establish a research network to support the advancement of biomedical research, improve human health through genomics research, and accelerate integration of genomic and other omics data into clinical care.

  • Aggregate dataThrough study completion, average 10 years

    Aggregate molecular, genomic data, phenotypic and other health-related data in centralized and/or federated databases to be accessed by investigators for approved research purposes.

  • Re-Contact participantsThrough study completion, average 10 years

    Recontact participants for additional data collection, research participation opportunities, and return of results

  • Genetic biomarker identificationThrough study completion, average 10 years

    Identification and characterization of clinical, histological, molecular, and genetic biomarkers that are linked to disease, disease outcomes, or that might be used to improvise disease classification.

  • Exploration of genetic determinants of diseaseThrough study completion, average 10 years

    Exploration of the molecular and genetic underpinnings and determinants of disease, including disease risk, disease progression, treatment response, health economic outcomes, social or behavioral determinants of health, targets for therapeutic intervention, risk stratification, and other clinical indicators of interest.

  • Collection and analysis of Patient Reported OutcomesThrough study completion, average 10 years

    Collection and analysis of Patient Reported Outcomes (e.g. quality of life, physical function, symptom burden) associated with diseases that have a genetic or molecular etiology. Validation of disease-specific instruments to assess the impact of genetic screening.